Report error Found 71 Enz. Inhib. hit(s) with all data for entry = 7924
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 20nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 23.4nMpH: 8.0Assay Description:To assess the compounds potency in the H3K27me0 peptide (21–44)-based PRC2 enzymatic assay, compounds were serially diluted three-fold in DMSO t...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH1/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 50nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 53.5nMpH: 8.0Assay Description:To assess the compounds potency in the H3K27me0 peptide (21–44)-based PRC2 enzymatic assay, compounds were serially diluted three-fold in DMSO t...More data for this Ligand-Target Pair
Affinity DataKd: 82nMpH: 8.0 T: 2°CAssay Description:ITC experiments were performed by Auto ITC200 (Microcal) at 25 °C. ITC sample cell was filled with 10 μM PRC2 in titration buffer (25 mM HEPES p...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2/Polycomb protein EED [40-441]/Polycomb protein SUZ12 [559-739](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataKd: 114nMpH: 8.0 T: 2°CAssay Description:ITC experiments were performed by Auto ITC200 (Microcal) at 25 °C. ITC sample cell was filled with 10 μM PRC2 in titration buffer (25 mM HEPES p...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2 [406-821](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 4 [388-802](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 8 [30-404](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2 [807-1356](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 1 [184-712](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [563-993,D835Y](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase kinase 4(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [551-1089,V561D](Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetGamma-aminobutyric acid receptor subunit alpha-1(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 1 group I member 2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 1 group I member 2(Human)
Novartis Institutes For Biomedical Research
Novartis Institutes For Biomedical Research
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:All HMT reactions were performed as described previously [Nasveschuk et al., ACS Med. Chem. Lett., 5:378-383].More data for this Ligand-Target Pair
